Ambryon Biosciences

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Single-arm phase 2/3 trial (CLIMB THAL-111) of exagamglogene autotemcel (exa-cel, CTX001), CRISPR-Cas9-edited autologous CD34+ cells, in patients aged 12 to 35 with transfusion-dependent beta-thalassemia. At the interim analysis, 32 of 35 evaluable patients (91%) reached transfusion independence for at least 12 months.

StatusCompleted
PhasePhase 2 3
Primary Endpoint ResultMet
Enrollment59
Start Date2018-09-14
Primary Completion Date2025-11-13

Results Summary

No results are posted on ClinicalTrials.gov; the figures below come from the phase 3 interim analysis (NEJM 2024, data cutoff 16 January 2023, 52 treated patients, median follow-up 20.4 months). Transfusion independence for at least 12 months (hemoglobin 9 g/dL or higher without transfusion) occurred in 32 of 35 evaluable patients (91%; 95% CI 77 to 98; P<0.001 against a 50% response). Neutrophils and platelets engrafted in all 52 patients (median 29 and 44 days). During transfusion independence, mean total hemoglobin was 13.1 g/dL and mean fetal hemoglobin 11.9 g/dL. Serious adverse events occurred in 17 of 52 patients (33%), most commonly veno-occlusive liver disease (5 patients), attributed to busulfan. No deaths or cancers occurred. A later report (April 2025 cutoff) described 55 of 56 patients transfusion independent for at least 12 months.

Design Implications

Editing the erythroid-specific BCL11A enhancer reactivates fetal hemoglobin to levels that give transfusion independence in about 9 of 10 patients with transfusion-dependent beta-thalassemia, including beta0/beta0 genotypes that have no adult hemoglobin, so fetal hemoglobin induction does not depend on the underlying mutation. Benefit tracked stable editing of about 78% of bone marrow CD34+ alleles, which supports allelic editing as a practical manufacturing and release marker. The main toxicity came from the delivery procedure, not the edit: myeloablative busulfan caused veno-occlusive liver disease and grade 3 or 4 events in 88% of patients, and patients needed months to engraft. Gentler or non-genotoxic conditioning, or in vivo editing of stem cells, is the clearest route to wider access. Three patients with beta0/beta0-like genotypes and intact spleens reached transfusion independence late or not at all despite similar editing, so fetal hemoglobin kinetics, not editing level, may limit response.

Rationale

Exa-cel is autologous CD34+ hematopoietic stem and progenitor cells edited ex vivo with CRISPR-Cas9 and a single guide RNA at the erythroid-specific enhancer of BCL11A. BCL11A represses gamma-globin, so disrupting its enhancer in the erythroid lineage reactivates fetal hemoglobin (HbF). In beta-thalassemia, HbF can replace the missing adult beta-globin and balance the globin chains, as in patients who co-inherit hereditary persistence of fetal hemoglobin. Raising HbF and total hemoglobin was expected to remove the need for red-cell transfusions.

Limitations

Single-arm, open-label trial with no control group. The efficacy analysis covers only the 35 of 52 treated patients with at least 16 months of follow-up at a prespecified interim cutoff (median follow-up 20.4 months); the final analysis is not posted or published. Registered as phase 2/3 though titled phase 1/2/3. Sponsor-funded, ages 12 to 35 only, and the treatment required myeloablative busulfan.

Registry record

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Primary OutcomesProportion of participants achieving transfusion independence for at least 12 consecutive months (TI12), Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days), Time to neutrophil and platelet engraftment, Frequency and severity of collected adverse events (AEs), Incidence of transplant-related mortality (TRM), All-cause mortality
KeywordsCRISPR-Cas9, Beta-Thalassemia, Hemoglobinopathies
Registry Last Updated2025-12-17
Minimum Age12 Years
Modalitiesgene_editing, cell_therapy
Maximum Age35 Years
Intervention NamesCTX001, Exagamglogene autotemcel, Exa-cel
AllocationNot Applicable
MaskingNone
Primary PurposeTreatment
Has ResultsNo
Enrollment TypeActual
CountriesUnited States, Canada, Germany, Italy, United Kingdom
Intervention Typesbiological
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsBeta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies, beta-Thalassemia
Completion Date2025-11-13
Lead Sponsor ClassIndustry
Eligibility SexAll

Official Title

A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia

Eligibility Criteria

Key Inclusion Criteria:

  • Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by

    1. Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning
    2. History of at least 100 mL/kg/year or ≥10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening
  • Eligible for autologous stem cell transplant as per investigator's judgment

Key Exclusion Criteria:

  • A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement
  • Prior allo-HSCT
  • Participants with associated α-thalassemia and >1 alpha deletion or alpha multiplications
  • Participants with sickle cell beta thalassemia variant
  • Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator
  • White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism

Other protocol defined Inclusion/Exclusion criteria may apply.

Identifiers & revision